Novo Nordisk (NOVO) Q3 2024 earnings summary

Executive summary

• Sales grew 24% at constant exchange rates in the first nine months of 2024, driven by strong demand for GLP-1-based diabetes and obesity treatments, with operating profit up 22% and net profit up 18%.

• GLP-1 portfolio was the main growth driver, with global GLP-1 market share rising to 65% and patient reach surpassing 43 million.

• Obesity care sales surged 44%, rare disease sales increased 3%, and free cash flow reached DKK 71.8 billion.

• Significant R&D progress with positive phase III results for SOUL, STRIDE, and ESSENCE trials, supporting semaglutide's broad cardiometabolic benefits.

• Executive management changes announced, including new leadership for US operations effective January 2025.

Financial highlights

• Sales: DKK 204.7 billion, up 24% at constant exchange rates; operating profit: DKK 91.6 billion, up 22% at constant exchange rates.

• Gross margin increased to 84.6% from 84.5% year-over-year, with operating margin at 44.7%.

• Net profit: DKK 72.8 billion, up 18%; diluted EPS: DKK 16.29, up 19% year-over-year.

• Free cash flow was DKK 71.8 billion, down from DKK 75.6 billion, reflecting higher capital expenditure.

• Research and development costs increased 56% year-over-year, including a DKK 5.7 billion impairment for ocedurenone.

Outlook and guidance

• 2024 sales growth guidance narrowed to 23–27% at constant exchange rates, with operating profit growth expected between 21–27%.

• Free cash flow expected between DKK 57–65 billion; capital expenditure forecasted at DKK 45 billion.

• Catalent acquisition expected to close by year-end, with a low single-digit negative impact on 2024 operating profit.

• 2025 sales growth expected in the high teens, reflecting a higher base and normalization of U.S. gross-to-net adjustments.

• Guidance reflects continued strong demand for GLP-1-based treatments and ongoing supply constraints.